期刊文献+

吉西他滨联合氟尿嘧啶和顺铂治疗晚期胰腺癌 被引量:3

Treatment of advanced pancreatic cance with gemcitabine,5-FU and cisplatine
下载PDF
导出
摘要 目的 :观察吉西他滨 (GEM)、氟尿嘧啶 (5 FU)及顺铂 (DDP)三药联合化疗对晚期胰腺癌的客观疗效及其临床受益反应 (CBR)。方法 :GEM 80 0mg m2 ,5 FU 6 0 0mg m2 ,DDP 30mg m2 ,于第 1、8、15天静滴 ,2 8天为1周期 ,按WHO标准评价疗效 ,同时综合评估临床受益反应 (CBR)指标 :疼痛、体力状况及体重变化。结果 :全组共 2 9例。 2 5例化疗两周期以上 ,其中PR 6例 (2 4 0 %) ,NC 12例 (4 8 0 %) ,PC 7例 (2 8 0 %)。参照CBR综合指标 ,CBR率为 6 2 1%(18 2 9)。主要毒性为消化道反应及骨髓抑制 ,其中血小板Ⅲ—Ⅳ度毒性为 2 7 6 %(18 2 9)。失访 18例。结论 :吉西他滨联合氟尿嘧啶及顺铂对晚期胰腺癌具有一定的肿瘤客观缓解率 ,临床受益反应率高 ,毒副反应能耐受 ,值得进一步研究。 Purpose:To observe the curative effect and the clinical-benefit-response of patients with advanced pancreatic cancer who used a combine of Gemcitabine,5-FU and PDD.Methods:The treatment with Gemcitabine (800 mg/m 2) was followed by 5-FU(600 mg/m 2) and DDP (30 mg/m 2),administered on days 1,8 and 15 of 28-day schedule. The curative effect was estimated according to the standard of WHO and the clinical benefit response was evaluated at the same time. The standard of CBR included pain,physical states and body weight. Results:Twenty-five (25/29) patients received over two cycles chemotherapy. 6(24%) partial response (PR), 12 (48%) stable disease and 7(28%) progressive disease were observed. According to the standard of CBR, 18(62.1%) patients achieved the clinical-benefit-response level. Therapy was well tolerated. The main toxicities included that the alimentary tract reactions and the marrow depression. Grade 3-4 thrombocytopenia was reported in 8 (27.6%) patients. Conclusions:The combination of GEM, 5-FU and DDP is a moderatedly active treatment with tolerable side-effects. It has definite response rate and high CBR rate in pancreatic cancer.
出处 《中国癌症杂志》 CAS CSCD 2001年第6期516-518,共3页 China Oncology
关键词 胰腺肿瘤 吉西他滨 药物联合治疗 氟尿嘧啶 顺铂 pancreatic cancer gemcitabine clinical benefit response
  • 相关文献

参考文献9

  • 1Hoffman JP, Lipsitz S, Pisansky T, et al.Phase Ⅱ trial of preoperative radiation therapy and chemotherapy for patiens with localized, respectable adenocarcinoma of the pancreas:An Eastern Cooperative Oncology Group study[J].J Clin Oncol,1998,16(1):317-323.
  • 2Bremback FH, Schoppmeyer K, Leupold U, etal. A phase Ⅱpolit of 13-cisretinoic acid and interferon-αin patients with advanced pancreatic carcinoma[J].Cancer,1998,83(11);2317-2323.
  • 3Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma[J].JAMA,1985,253(4):2061-2067.
  • 4Buroker TR,O'Connell MJ, Wieand HJ, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of davanced colorectal cancer[J].J Clin Oncol,1994,12(1):14-20.
  • 5Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403-2413.
  • 6王肇炎.第13届亚太癌症会议内科肿瘤学的进展[J].中国肿瘤,1997,6(4):22-23. 被引量:3
  • 7徐家廉.健择和晚期胰腺癌[J].中国癌症杂志,2000,10(5):434-437. 被引量:28
  • 8Stomiolo AM, Enas NH, Brown CA, et al. New drug gemcitabine treatment program for over 3000 patients with pancreas carcinoma[J].Cnacer,1999,85(6):1261-1268.
  • 9Manual H, Danial C,Luis PA, et al.Phase Ⅰ-Ⅱ study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer[J].J Clin Oncol,1999,17(2):585-592.

二级参考文献1

  • 1张天泽 徐光炜.肿瘤学[M].天津:天津技术出版社,1998.1402.

共引文献29

同被引文献15

引证文献3

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部